Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genzyme Receives Company Award

Published: Thursday, February 28, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
Genzyme, announced that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases.

The EURORDIS Company Award recognizes the outstanding accomplishments of companies dedicated to rare diseases. Genzyme was honored for pioneering the development and delivery of therapies for rare diseases, its longstanding support of patient organizations, including EURORDIS, as well as initiatives to increase patient access to Genzyme treatments.

EURORDIS Award recipients are selected by the EURORDIS Board of Directors, from over 100 nominations received from EURORDIS members (rare disease patient advocacy groups from all Europe), volunteers and staff, with the aim of promoting leadership and excellence for people living with rare diseases. Genzyme’s Senior Vice President of Rare Diseases in Europe, Hilde Furberg, accepted the award yesterday during the EURORDIS Black Pearl Gala Dinner in Brussels as EURORDIS began its activities to recognize International Rare Disease Day.

“Genzyme has been partnering with patient advocacy organizations globally from our earliest days to be sure the community’s needs and perspectives are always represented within our organization, and the contributions of these organizations remain central to Genzyme and our ability to bring therapies to patients,” said Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD. “As we approach Rare Disease Day, a day made possible because of EURORDIS, Genzyme wants to thank all of the patient organizations and communities who work daily to improve the lives of patients living with rare diseases. Their pioneering spirit will continue to inspire Genzyme.”

Yann Le Cam, Chief Executive Officer of EURORDIS, said, "We are honored to acknowledge the commitment and achievements of this year’s recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of this year’s ten awardees contributes in their own unique way toward fostering the goals of cooperation embodied in this year’s Rare Disease Day slogan: ‘Rare Disorders without Borders.’ We are proud that the rare disease community is becoming a model for multi-stakeholder partnership and international collaboration as well as for solidarity and unity throughout Europe.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme, Ablynx Launch MS Collaboration
Genzyme has agreed to use Ablynx's therapeutic proteins to carry out in vitro and in vivo research on multiple sclerosis models, then develop therapies against the disease.
Tuesday, May 19, 2015
Genzyme’s LEMTRADA™ Application for MS Accepted for Review by the FDA
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
Tuesday, January 29, 2013
Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!